Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
Authors:
- 19 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (5) , 1553-1563
Abstract
Background and Aims: There are limited data on the progression of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in people with type 2 diabetes mellitus (T2DM) versus those without T2DM in biopsy-proven metabolic dysfunction–associated steatotic liver disease. We examined LSM progression in participants with T2DM versus those without T2DM in a large, prospective, multicenter cohort study. Approach and Results: This study included 1231 adult participants (62% female) with biopsy-proven metabolic dysfunction–associated steatotic liver disease who had VCTEs at least 1 year apart. LSM progression and regression were defined by a ≥20% increase and an upward or downward change, respectively, in the LSM category in the Baveno VII categories for compensated advanced chronic liver disease, compared between participants with T2DM (n = 680) versus no T2DM (n = 551) at baseline. The mean (±SD) age and body mass index were 51.8 (±12.0) years and 34.0 (±6.5) kg/m2, respectively. The median (IQR) time between the first and last VCTE measurements was 4.1 (2.5–6.5) years. Participants with T2DM had higher LSM progression at 4 years (12% vs. 10%), 6 years (23% vs. 16%), and 8 years (50% vs. 39%), p = 0.04. Using a multivariable Cox proportional hazards model adjusted for multiple confounders, the presence of T2DM remained an independent predictor of LSM progression (adjusted HR: 1.35, 95% CI: 1.01–1.81, p = 0.04). T2DM was not associated with LSM regression (p = 0.71). Mean HbA1c was significantly associated with LSM progression (p = 0.003) and regression (p = 0.02). Conclusions: Using serial VCTE data from a multicenter study of participants with biopsy-proven metabolic dysfunction–associated steatotic liver disease, we demonstrate that T2DM and HbA1c are associated with LSM progression.Keywords
This publication has 42 references indexed in Scilit:
- Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver DiseaseJAMA, 2024
- Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASHHepatology, 2022
- Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLDHepatology, 2022
- Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancerCell Metabolism, 2022
- Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver DiseaseClinical Gastroenterology and Hepatology, 2021
- Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver DiseaseHepatology, 2021
- Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLDHepatology, 2020
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005